Asahi Chemical Trains Apheresis Specialists For Chinese Hospitals
This article was originally published in PharmAsia News
Executive SummaryTokyo-based medical device maker Asahi Chemical Kuraray Medical established the Apheresis Training Center in Beijing. In collaboration with Captial Medical University's Youan Hospital, Asahi Chemical will use the center to train physicians and nurses for apheresis and dialysis treatments in Chinese hospitals. Youan Hospital has used apheresis to treat over 18,000 patients with liver disease, and apheresis is gaining popularity in China as a key treatment for patients with multi-organ failure, liver failure and intractable autoimmune disorders. The company also plans to launch satellite training centers in other major Chinese cities such as Shanghai and Guangzhou. Asahi also looks to establish similar training facilities in the U.S. and Canada. (Click here for more - Japanese language
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.